The study found that urine (tissue inhibitor of metalloproteinase-2 [TIMP-2]) × (Insulin-like growth factor binding protein 7 [IGFBP7]) concentrations were of practical screening value to recognize high-risk patients of moderate to severe AKI (KDIGO stages 2 and 3) within the first seven days of ICU admission. This evidence concerns the gene TIMP2 and acute kidney injury.